These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27546593)

  • 1. Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems.
    Rodrigues D; Monteiro M; Jerónimo C; Henrique R; Belo L; Bastos ML; Guedes de Pinho P; Carvalho M
    Transl Res; 2017 Feb; 180():1-11. PubMed ID: 27546593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urine metabolomic analysis in clear cell and papillary renal cell carcinoma: A pilot study.
    Oto J; Fernández-Pardo Á; Roca M; Plana E; Solmoirago MJ; Sánchez-González JV; Vera-Donoso CD; Martínez-Sarmiento M; España F; Navarro S; Medina P
    J Proteomics; 2020 Apr; 218():103723. PubMed ID: 32126320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
    Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
    Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine metabolomics analysis for kidney cancer detection and biomarker discovery.
    Kim K; Aronov P; Zakharkin SO; Anderson D; Perroud B; Thompson IM; Weiss RH
    Mol Cell Proteomics; 2009 Mar; 8(3):558-70. PubMed ID: 19008263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers in bladder cancer: A metabolomic approach using in vitro and ex vivo model systems.
    Rodrigues D; Jerónimo C; Henrique R; Belo L; de Lourdes Bastos M; de Pinho PG; Carvalho M
    Int J Cancer; 2016 Jul; 139(2):256-68. PubMed ID: 26804544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing maps.
    Zheng H; Ji J; Zhao L; Chen M; Shi A; Pan L; Huang Y; Zhang H; Dong B; Gao H
    Oncotarget; 2016 Sep; 7(37):59189-59198. PubMed ID: 27463020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated transcriptomic and metabolomic analysis shows that disturbances in metabolism of tumor cells contribute to poor survival of RCC patients.
    Popławski P; Tohge T; Bogusławska J; Rybicka B; Tański Z; Treviño V; Fernie AR; Piekiełko-Witkowska A
    Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):744-752. PubMed ID: 28012969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolomics in renal cell carcinoma: From biomarker identification to pathomechanism insights.
    Chen YY; Hu HH; Wang YN; Liu JR; Liu HJ; Liu JL; Zhao YY
    Arch Biochem Biophys; 2020 Nov; 695():108623. PubMed ID: 33039388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic profiling reveals key metabolic features of renal cell carcinoma.
    Catchpole G; Platzer A; Weikert C; Kempkensteffen C; Johannsen M; Krause H; Jung K; Miller K; Willmitzer L; Selbig J; Weikert S
    J Cell Mol Med; 2011 Jan; 15(1):109-18. PubMed ID: 19845817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of metabolomics-derived biomarkers to identify renal cell carcinoma: a comprehensive perspective of the past ten years and advancements.
    Gupta A; Nath K; Bansal N; Kumar M
    Expert Rev Mol Diagn; 2020 Jan; 20(1):5-18. PubMed ID: 31825678
    [No Abstract]   [Full Text] [Related]  

  • 11. Metabolomics informs common patterns of molecular dysfunction across histologies of renal cell carcinoma.
    DiNatale RG; Sanchez A; Hakimi AA; Reznik E
    Urol Oncol; 2020 Oct; 38(10):755-762. PubMed ID: 31155438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma.
    Lucarelli G; Loizzo D; Franzin R; Battaglia S; Ferro M; Cantiello F; Castellano G; Bettocchi C; Ditonno P; Battaglia M
    Expert Rev Mol Diagn; 2019 May; 19(5):397-407. PubMed ID: 30983433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma.
    Gremel G; Djureinovic D; Niinivirta M; Laird A; Ljungqvist O; Johannesson H; Bergman J; Edqvist PH; Navani S; Khan N; Patil T; Sivertsson Å; Uhlén M; Harrison DJ; Ullenhag GJ; Stewart GD; Pontén F
    BMC Cancer; 2017 Jan; 17(1):9. PubMed ID: 28052770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathway analysis of kidney cancer using proteomics and metabolic profiling.
    Perroud B; Lee J; Valkova N; Dhirapong A; Lin PY; Fiehn O; Kültz D; Weiss RH
    Mol Cancer; 2006 Nov; 5():64. PubMed ID: 17123452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin D1 as a therapeutic target of renal cell carcinoma- a combined transcriptomics, tissue microarray and molecular docking study from the Kingdom of Saudi Arabia.
    Karim S; Al-Maghrabi JA; Farsi HM; Al-Sayyad AJ; Schulten HJ; Buhmeida A; Mirza Z; Al-Boogmi AA; Ashgan FT; Shabaad MM; NourEldin HF; Al-Ghamdi KB; Abuzenadah A; Chaudhary AG; Al-Qahtani MH
    BMC Cancer; 2016 Sep; 16(Suppl 2):741. PubMed ID: 27766950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA.
    Nizioł J; Bonifay V; Ossoliński K; Ossoliński T; Ossolińska A; Sunner J; Beech I; Arendowski A; Ruman T
    Anal Bioanal Chem; 2018 Jun; 410(16):3859-3869. PubMed ID: 29658093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma.
    Monteiro MS; Barros AS; Pinto J; Carvalho M; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Guedes de Pinho P
    Sci Rep; 2016 Nov; 6():37275. PubMed ID: 27857216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
    Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
    BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Metabonome in Early Diagnosis of Renal Cell Carcinoma].
    Wang Z; Zhang YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Oct; 41(5):709-713. PubMed ID: 31699205
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.